Triple-receptor structure and signaling research on GLP-3 R
GLP-3 R is a triple-agonist analog studied through coordinated engagement of GLP-1, GIP, and glucagon receptors.
Overview
GLP-3 R is presented as a next-generation GLP-family peptide corresponding to retatrutide research. Its defining laboratory feature is not a new “GLP-3” receptor; it is activity across three established class B receptors: GLP-1R, GIPR, and the glucagon receptor.
Cryo-electron microscopy and mutational assays have mapped how retatrutide occupies each receptor and which contacts influence cyclic-AMP signaling. Comparative pharmacology also highlights a central experimental challenge: one peptide can display different potency and efficacy across three receptors, cell systems, and assay endpoints.
This makes GLP-3 R relevant to multi-receptor binding and signaling research. The evidence does not mean a VIVO material was evaluated in the cited work, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Li W, Zhou Q, Cong Z, et al. (2024). Structural insights into triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery; 10:77. View source ↗
- Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: receptor pharmacology and preclinical characterization. Cell Metabolism; 34(9):1234–1247. View source ↗
- Finan B, Yang B, Ottaway N, et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine; 21:27–36. View source ↗